Alternatives
An AlphaSense alternative — when you need the answer.
AlphaSense is an excellent way to find something. It is not a way to be told something. For a single-asset oncology company, that difference decides the purchase.
People look for an AlphaSense alternative when the search itself was never the bottleneck. The platform does find the passage — the problem is that someone still has to know which question to ask, ask it every week, read what comes back, and work out what it does to their own programme.
For a company with a CI team, that is exactly the right division of labour. For a company where competitive intelligence is a task on a CBO's evening, the missing piece is not search.
What AlphaSense actually is
AlphaSense is a market-intelligence search platform: a large indexed corpus — company filings, earnings-call transcripts, expert interviews, broker research, news and, for subscribers, their own internal documents — with AI-assisted search and summarisation over the top. It is widely used in financial services and corporate strategy.
It is very good at what it is. Semantic search across a corpus that size is genuinely hard, the transcript and expert-content library is a real asset, and for someone with a specific question and the judgement to evaluate the answer it compresses hours of work into minutes. Nothing here disputes that.
What Prognyx is
Prognyx is a delivered oncology competitive-intelligence service. Nobody logs in and nobody writes a query: the watch runs continuously against your competitive set, and when something moves you get a brief explaining what happened, what it means for your asset and what to do — every claim traced to the primary record.
| Dimension | AlphaSense | Prognyx |
|---|---|---|
| What you buy | A search and AI-summarisation layer over a large document corpus | A person’s output — a written read on your competitive set |
| Core strength | Finding the passage, fast, across filings, transcripts and research | Deciding what the passage means for your asset |
| Who asks the questions | You. The quality of the answer tracks the quality of your query | Prognyx, continuously, without being asked |
| Domain depth | Broad — built for finance and cross-industry research | Oncology only |
| Trial-level detail | Whatever appears in the indexed documents | The registry record itself, re-verified at publication |
| Mode | Pull — you go looking when you think to look | Push — the brief arrives when something moves |
| AI summaries | A core feature of the product | Never the final word: a human decides what is true |
| Seats | Priced per seat | Not applicable |
| Accountability for a wrong read | Yours | One named analyst, publicly |
| Published pricing | Not published | Published — from $2,000/mo |
When AlphaSense is the better buy
- Your questions are unpredictable and constant. If the need is "let me look something up across the market five times a day", a search platform is exactly right and a briefing service is not.
- You need earnings transcripts and broker research. That corpus is a genuine differentiator, and Prognyx does not have it.
- You want to search your own internal documents alongside external ones. Not something Prognyx does.
- Your remit spans sectors. Diligence across therapeutic areas, devices, diagnostics, or beyond healthcare entirely.
- You have the judgement in-house and only lack retrieval speed. Then buy retrieval speed.
When Prognyx is the better buy
- Nobody is going to run the searches. A pull tool only works if someone reliably pulls. The competitive move that hurts is the one nobody thought to look for that week.
- The question is oncology-specific and technical. Whether a hazard ratio of 0.76 disclosed without a p-value clears a regulator's stated significance bar is not a retrieval problem. It is a reading problem.
- You need the primary record, not the coverage of it. Prognyx cites the registry entry, the SEC exhibit, the FDA action — and re-verifies each cited trial against the live registry immediately before publishing, because registry lag is a real failure mode.
- An AI summary is not enough to act on. Summaries are fast and are the right first step; a decision needs someone accountable for whether the summary is correct. Here that is Rali Filali, and the procedure is published.
- You want a forwardable artefact. A brief goes to your board or your co-founder as-is. A search session does not.
The AI question, directly
Both products use machine intelligence, so "we use AI" distinguishes nothing in 2026. The distinction worth asking about is where the human decision sits.
Prognyx uses machines to read widely and never to decide what is true: an analysis is drafted, then re-checked claim by claim against its cited source by a separate pass that distrusts by default, then a named human decides whether it publishes. When a fact cannot be confirmed, the brief says so in those words rather than producing a fluent sentence. That is the whole difference between a summary and a read you can act on.
Using both
They compose well and there is no reason to frame it otherwise. A team can keep a search platform for ad-hoc questions across the market and use Prognyx for continuous depth on the two or three assets that actually determine the company's value.
How to decide in one question
Ask what happens on a week when nobody has time. With a search platform, nothing happens — and nothing happening is invisible until a competitor's abstract is already public. With a delivered service, the brief still arrives. Buy for the busy week, not the ideal one.
Comparison last reviewed 25 July 2026. This page describes AlphaSense from its public product information and does not claim to be exhaustive; AlphaSense does not publish list pricing, and nothing here invents any. Prognyx has no affiliation with AlphaSense. Verify current scope and pricing with the vendor directly before any purchase decision. Names and trademarks referenced belong to their owners.
Frequently asked
What is the best AlphaSense alternative for a biotech?
If you need search across filings and transcripts, the alternatives are other search platforms. If what you actually need is for somebody to watch your competitive set and tell you what changed, the alternative is a delivered service — Prognyx does that for oncology, from $2,000/mo, with every claim traced to a primary source.
Does Prognyx replace AlphaSense?
Only if search was never the real gap. Prognyx has no document search interface, no transcript library and no cross-sector corpus. What it replaces is the unstaffed expectation that someone will find time to use one.
Is Prognyx just AI-generated summaries?
No. Machines sweep sources and draft; a separate audit pass re-checks every claim against its cited primary source; and a named human decides whether each fact is true and whether the brief publishes. Unconfirmable facts are published as unconfirmed rather than smoothed over. The full procedure is on how we work.
How does Prognyx handle clinical-trial data specifically?
From the registry record itself rather than from documents that mention it — status, arms, enrolment, endpoints, termination reasons and dates — and every cited trial is re-verified against the live registry at publication time, because a status that changed since the source was written is the failure mode ordinary fact-checking misses.
Judge it on a brief, not a demo.
Name one asset you'd want watched. You get a real competitive brief on it — free, sourced, no obligation.
Request a sample brief → Compare with Cortellis